Autopsy report · NCT01914718

Dose-adjusted EPOCH-R in MYC Positive DLBCL

“Poor accrual of eligible patients”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 10 months before it stopped.
• 26 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Fudan University

Sponsor type

University, hospital or other

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DA-EPOCH-R

Participants

26 (planned, not actual)

Sites

1

Countries

China

Trials that died the same way

• Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study
  “poor patient accrual” (89% match in meaning)
• Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
  “Inadequate patient accrual” (84% match in meaning)
• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (83% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (78% match in meaning)
• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
  “Not enough eligible patients available” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.